コンテンツへスキップ
Merck
  • Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion.

Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion.

eLife (2021-10-01)
Akikazu Harada, Shinji Matsumoto, Yoshiaki Yasumizu, Kensaku Shojima, Toshiyuki Akama, Hidetoshi Eguchi, Akira Kikuchi
要旨

Pancreatic cancer has a high mortality rate due to metastasis. Whereas KRAS is mutated in most pancreatic cancer patients, controlling KRAS or its downstream effectors has not been succeeded clinically. ARL4C is a small G protein whose expression is induced by the Wnt and EGF-RAS pathways. In the present study, we found that ARL4C is frequently overexpressed in pancreatic cancer patients and showed that its localization to invasive pseudopods is required for cancer cell invasion. IQGAP1 was identified as a novel interacting protein for ARL4C. ARL4C recruited IQGAP1 and its downstream effector, MMP14, to invasive pseudopods. Specific localization of ARL4C, IQGAP1, and MMP14 was the active site of invasion, which induced degradation of the extracellular matrix. Moreover, subcutaneously injected antisense oligonucleotide against ARL4C into tumor-bearing mice suppressed metastasis of pancreatic cancer. These results suggest that ARL4C-IQGAP1-MMP14 signaling is activated at invasive pseudopods of pancreatic cancer cells.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
抗ミトコンドリア抗体、無傷ミトコンドリアの表面、クローン113-1, clone 113-1, Chemicon®, from mouse
Sigma-Aldrich
抗コルタクチン(p80/85)抗体、クローン4F11, clone 4F11, Upstate®, from mouse
Sigma-Aldrich
Anti-ARL4C antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
PD-184161, ≥98% (HPLC)